Preview

Эпидемиология и Вакцинопрофилактика

Расширенный поиск

Факторы риска развития злокачественных новообразований головы и шеи

https://doi.org/10.31631/2073-3046-2021-20-1-92-99

Полный текст:

Аннотация

Актуальность. В последнее время во всем мире отмечается рост заболеваемости раком головы и шеи. Рак головы и шеи – одна из самых распространенных форм рака, на которую приходится 5–10% всех онкологических заболеваний в мире. В структуре смертности от рака он занимает 8-е место.

Цель. Осветить основные факторы риска развития злокачественных новообразований головы и шеи, а также этиологическую роль вируса папилломы человека.

Выводы. В настоящее время именно рост распространенности вирусных инфекций считается основной причиной увеличения заболеваемости плоскоклеточным раком области головы и шеи, причем данная патология чаще наблюдается среди некурящих мужчин средних лет с высоким социально-экономическим статусом, имеющих орально-генитальные половые контакты с несколькими половыми партнерами, а также плохой стоматологический статус.

Об авторе

Е. Н. Белякова
ФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет)
Россия

Екатерина Николаевна Белякова – аспирант

119991, Москва, ул. Трубецкая, д. 8, стр.2.



Список литературы

1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2014;136(5):E359–E386. doi:10.1002/ijc.29210.

2. Lydiatt, W. M., Patel, S. G., O’Sullivan, B., et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians. 2017;67(2):122–137. doi:10.3322/caac.21389.

3. Chow, Laura K.M. Head and neck cancer. Edited by Dan L. Longo. New England Journal of Medicine 382, no. 1 (January 2, 2020):60–72. doi.org/10.1056/NEJMra1715715.

4. World Cancer Research Fund. American Institute for Cancer Research. Continuous Update Project Findings & Reports.

5. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185. countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi:10.3322/caac.21492.

6. International Agency for Research on Cancer. List of Classifications by cancer sites with sufficient or limited evidence in humans, Volumes 1 to 122.

7. Brown, K. F., Rumgay, H., Dunlop, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. British Journal of Cancer, 2018;118(8):1130–1141. doi:10.1038/s41416-018-0029-6.

8. Wyss, A., Hashibe, M., Chuang, S.-C., et al. Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. American Journal of Epidemiology, 2013;178(5):679–690. doi:10.1093/aje/kwt029.

9. Muscat, J. E., Liu, H.-P., Livelsberger, C., et al. The nicotine dependence phenotype, time to first cigarette, and larynx cancer risk. Cancer Causes & Control, 2012;23(3):497–503. doi:10.1007/s10552-012-9909-x.

10. Gandini, S., Botteri, E., Iodice, S., et al. Tobacco smoking and cancer: A meta-analysis. International Journal of Cancer, 2007;122(1):155–164. doi:10.1002/ijc.23033.

11. Long, M., Fu, Z., Li, P., et al. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. BMJ Open. 2017;7(10):e016582. doi:10.1136/bmjopen-2017-016582.

12. Maasland, D. H., van den Brandt, P. A., Kremer, B., et al. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study. BMC Cancer, 2014;14(1). doi:10.1186/1471-2407-14-187.

13. Asthana, S., Labani, S., Kailash, U., et al. Association of Smokeless Tobacco Use and Oral Cancer: A Systematic Global Review and Meta-Analysis. Nicotine & Tobacco Research, 2018;21(9):1162–1171. doi:10.1093/ntr/nty074.

14. World Health Organization. Global status report on alcohol and health. Geneva 2018.

15. Testino G. The burden of cancer attributable to alcohol consumption. Maedica (Bucur). 2011;6(4):313–20. PMID: 22879847; PMCID: PMC3391950.

16. Mons, U., Gredner, T., Behrens, G., et al. Cancers due to smoking and high alcohol consumption. Deutsches Aerzteblatt Online. 2018. doi:10.3238/arztebl.2018.0571.

17. Lee, Y. A., Li, S., Chen, Y., et al. Tobacco smoking, alcohol drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population. Head & Neck. 2018. doi:10.1002/hed.25383.

18. Plummer, M., de Martel, C., Vignat, J., et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health, 2016;4(9):e609–e616. doi:10.1016/s2214-109x(16)30143-7.

19. Tsao, S. W., Tsang, C. M., Lo, K. W. Epstein–Barr virus infection and nasopharyngeal carcinoma. Philosophical Transactions of the Royal Society B: Biological Sciences. 2017;372(1732):20160270. doi:10.1098/rstb.2016.0270.

20. Young, L. S., Yap, L. F., Murray, P. G. Epstein–Barr virus: more than 50 years old and still providing surprises. Nature Reviews Cancer, 2016;16(12):789–802. doi:10.1038/nrc.2016.92.

21. Rautava, J., & Syrjänen, S. Biology of Human Papillomavirus Infections in Head and Neck Carcinogenesis. Head and Neck Pathology. 2012;6(S1):3–15. doi:10.1007/s12105-012-0367-2.

22. Anantharaman, D., Abedi-Ardekani, B., Beachler, D. C., et al. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer. International Journal of Cancer. 2017;140(9):1968–1975. doi:10.1002/ijc.30608.

23. Roman, A., Munger, K. The papillomavirus E7 proteins. Virology. 2013;445(1–2):138–168. doi:10.1016/j.virol.2013.04.013.

24. Albano, P. M., Holzinger, D., Salvador, C., et al. Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in the northwest region of the Philippines. PLOS ONE. 2017;12(2):e0172240. doi:10.1371/journal.pone.0172240.

25. Onerci Celebi, O., Sener, E., Hosal, S., et al. Human papillomavirus infection in patients with laryngeal carcinoma. BMC Cancer. 2018;18(1). doi:10.1186/s12885-018-4890-8

26. Castellsagué X, Alemany L, Quer M, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst. 2016; 108(6):djv403. doi: 10.1093/jnci/djv403. PMID: 26823521.

27. Wittekindt, C., Wagner, S., Sharma, S., et al. HPV – Das andere Kopf-Hals-Karzinom. Laryngo-Rhino-Otologie, 2018;97(S 01):S48–S113. doi:10.1055/s-0043-121596.

28. Stenmark, M. H., Shumway, D., Guo, C., et al. Influence of human papillomavirus on the clinical presentation of oropharyngeal carcinoma in the United States. The Laryngoscope, 2017;127(10), 2270–2278. doi:10.1002/lary.26566.

29. D’Souza, G., Zhang, H. H., D’Souza, et al. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncology. 2010;46(2):100–104. doi:10.1016/j.oraloncology.2009.11.004.

30. Gillison, M. L., Broutian, T., Pickard, R. K. L., et al. Prevalence of Oral HPV Infection in the United States, 2009–2010. JAMA. 2012;307(7):693. doi:10.1001/jama.2012.101

31. Fakhry, C., Westra, W. H., Wang, S. J., et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017;123(9):1566–1575. doi:10.1002/cncr.30353.

32. Meng, H., Miao, S., Chen, K., et al. Association of p16 as Prognostic Factors for Oropharyngeal Cancer: Evaluation of p16 in 1470 Patients for a 16 Year Study in Northeast China. BioMed Research International, 2018:1–8. doi:10.1155/2018/9594568.

33. Wookey VB, Appiah AK, Kallam A, et al. HPV status and survival in non-oropharyngeal squamous cell carcinoma of the head and neck. Anticancer Res. 2019;39(4):1907–1914. doi:10.21873/anticanres.13299.

34. Duray, A., Descamps, G., Decaestecker, C., et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. The Laryngoscope, 2012;122(7):558–1565. doi:10.1002/lary.23298.

35. Salazar, C. R., Anayannis, N., chi, R. V., et al. Combined P16 and human papillomavirus testing predicts head and neck cancer survival. International Journal of Cancer, 2014;135(10):2404–2412. doi:10.1002/ijc.28876.

36. Janecka-Widła, A., Mucha-Małecka, A., Majchrzyk, K., et al. Active HPV infection and its influence on survival in head and neck squamous-cell cancer. Journal of Cancer Research and Clinical Oncology. 2020;146(7):1677–1692. doi:10.1007/s00432-020-03218-6.

37. Fakhry, C., Westra, W. H., Li, S., et al. Improved Survival of Patients with Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. JNCI Journal of the National Cancer Institute. 2008;100(4):261–269. doi:10.1093/jnci/djn011.

38. Biesaga, B., Mucha-Małecka, A., Janecka-Widła, A., et al. Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16. Journal of Cancer Research and Clinical Oncology. 2017;144(1):63–73. doi:10.1007/s00432-017-2531-2.

39. Yoo, S. H., Ock, C.-Y., Keam, B., et al. Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment? The Korean Journal of Internal Medicine. 2019;34(6):1313–1323. doi:10.3904/kjim.2017.397.

40. Tinhofer, I., Jöhrens, K., Keilholz, U., et al. Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. European Journal of Cancer. 2015;51(4):514–521. doi:10.1016/j.ejca.2014.12.018.

41. Tsai, S. C.-S., Huang, J.-Y., Lin, C., et al. The association between human papillomavirus infection and head and neck cancer. Medicine. 2019;98(7): e14436. doi:10.1097/md.0000000000014436.

42. Morshed, K. Association between human papillomavirus infection and laryngeal squamous cell carcinoma. Journal of Medical Virology. 2010;82(6):1017–1023. doi:10.1002/jmv.21749.

43. Mourad, M., Jetmore, T., Jategaonkar, A. A., et al. Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study. Journal of Oral and Maxillofacial Surgery. 2017;75(12):2562–2572. doi:10.1016/j.joms.2017.05.008.

44. Sonawane K, Suk R, Chiao EY, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med. 2017;167:714–724. doi: 10.7326/M17-1363.

45. Lafaurie GI, Perdomo SJ, Buenahora MR, et al. Human papilloma virus: an etiological and prognostic factor for oral cancer? J Investigativ Clin Dent. 2018;9:e12313. doi: 10.1111/jicd.12313.

46. Pedlow CT, Carey MP. Developmentally-appropriate sexual risk reduction interventions for adolescents: rationale, review of interventions, and recommendations for research and practice. Ann Behav Med. 2004;27:172–184. doi: 10.1207/s15324796abm2703_5.

47. Döring N, Daneback K, Shaughnessy K, et al. Online sexual activity experiences among college students: a four-country comparison. Arch Sex Behav. 2017;46:1641–1652. doi: 10.1007/s10508-015-0656-4.

48. Zeng, X.-T., Deng, A.-P., Li, C., et al. Periodontal Disease and Risk of Head and Neck Cancer: A Meta-Analysis of Observational Studies. PLoS ONE, 2013;8(10):e79017. doi:10.1371/journal.pone.0079017.

49. Zeng, X.-T., Luo, W., Huang, W., et al. Tooth Loss and Head and Neck Cancer: A Meta-Analysis of Observational Studies. PLoS ONE. 2013;8(11):e79074. doi:10.1371/journal.pone.0079074.

50. Manoharan, S., Nagaraja, V., Eslick, G. D. Ill-fitting denturesandoralcancer: Ameta-analysis. Oral Oncology, 2014;50(11):1058–1061. doi:10.1016/j.oraloncology.2014.08.002.

51. Tezal, M., Scannapieco, F. A., Wactawski-Wende, J., et al. Local Inflammation and Human Papillomavirus Status of Head and Neck Cancers. Archives of Otolaryngology–Head & Neck Surgery. 2012;138(7):669. doi:10.1001/archoto.2012.873.

52. Boss, E. F., Marsteller, J. A., Simon, A. E. Outpatient Tonsillectomy in Children: Demographic and Geographic Variation in the United States, 2006. The Journal of Pediatrics. 2012;160(5):814–819. doi:10.1016/j.jpeds.2011.11.041.

53. Surgical operations in short‐stay hospitals for discharged patients: United States – 1965. Vital Health Stat. 1971;13(April):1–8.

54. Chaturvedi, A. K., Song, H., Rosenberg, P. S., et al. Tonsillectomy and Incidence of Oropharyngeal Cancers. Cancer Epidemiology Biomarkers & Prevention, 2016;25(6):944– 950. doi:10.1158/1055-9965.epi-15-0907.

55. Altenhofen, B., DeWees, T. A., Ahn, J. W., et al. Childhood tonsillectomy alters the primary distribution of HPV‐related oropharyngeal squamous cell carcinoma. Laryngoscope Investigative Otolaryngology. 2020;5(2):210–216. doi:10.1002/lio2.342.

56. WHO/IVB Database, as at June 2020 Map production: Countries with HPV vaccine in the national immunization programme. Доступно на:/Available at: https://www.who. int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx. Accessed: November 2020.

57. Lowy, D. R. Prophylactic human papillomavirus vaccines. Journal of Clinical Investigation, 2006;116(5);1167–1173. doi:10.1172/jci28607.

58. Gardasil 9. Food and Drug Administration. Доступно на:/Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM42 457. pdf. Accessed: November 2020.

59. Giuliano, A. R., Palefsky, J. M., Goldstone, S., et al. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine, 2011;364(5):401–411. doi:10.1056/nejmoa0909537.

60. Palefsky, J. M., Giuliano, A. R., Goldstone, S., et al. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. New England Journal of Medicine, 2011;365(17):1576–1585. doi:10.1056/nejmoa1010971.

61. Muñoz, N., Manalastas, R., Pitisuttithum, P., et al. (2009). Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet, 2009;373(9679): 1949–1957. doi:10.1016/s0140-6736(09)60691-7.

62. Ferris, D., Samakoses, R., Block, S. L., et al. Long-term Study of a Quadrivalent Human Papillomavirus Vaccine. PEDIATRICS, 2014;134(3):e657–e665. doi:10.1542/peds.20134144.

63. Castellsagué X, Alemany L, Quer M, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst. 2016;108(6):djv403. doi: 10.1093/jnci/djv403. PMID: 26823521.

64. Дьяков, И.А. Фармакоэкономическая эффективность квадривалентной вакцины. //Медицинский совет. – 2016. – № 19. – С. 103–108.

65. Хрянин А. А. Решетников О., Коломиец Л. А. Новые возможности профилактики папилломавирусной инфекции. //Вестник дерматологии и венерологии. – 2009. – №5. – С.49–55.


Для цитирования:


Белякова Е.Н. Факторы риска развития злокачественных новообразований головы и шеи. Эпидемиология и Вакцинопрофилактика. 2021;20(1):92-99. https://doi.org/10.31631/2073-3046-2021-20-1-92-99

For citation:


Belyakova E.N. Risk Factors for the Development of Malignant Tumors of the Head and Neck. Epidemiology and Vaccinal Prevention. 2021;20(1):92-99. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-1-92-99

Просмотров: 254


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-3046 (Print)
ISSN 2619-0494 (Online)